Centaur Announces CFO Transition Plan
The Company has started a search to identify and select a new CFO and has retained executive search firm Crist|Kolder Associates to conduct the process.
“The Board and I thank Bob for his contributions to the Company and wish him and his family the best in the future,” said Woody. “Brian Busenlehner is a highly experienced finance professional, and I’m pleased to have him step into this role on an interim basis while the search for a new CFO is conducted.”
About Centaur
Centaur Guernsey L.P. Inc., through its subsidiaries KCI, LifeCell and Systagenix, is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 75 countries around the world. The three companies form one globally diversified wound care, biologics and regenerative medicine company, committed to advancing the science of medicine to reduce complications, speed healing and improve patient lives. Headquartered in San Antonio, Texas, the company is a leader in the medical technology industry with the most comprehensive offering of best-in-class surgical and chronic wound therapies. Additional information about the company and its products is available at www.KCI1.com.
Contact
KCI Corporate Communications
Mike Barger
+1-210-255-6824
mike.barger@kci1.com
KCI Investor Relations
Nathan Speicher
+1-210-255-6027
nathan.Speicher@kci1.com
This news is a press release provided by Centaur Guernsey L.P. Inc..